PATENT CLAIM ANALYSIS

Application Number: 15997020
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-07
Patent Classification: ["514", "161000"]

Abstract:
A method of treating a condition of in a human patient comprising pharmacologically activating a translocator protein of 18 kDa (TSPO), wherein the condition is one of a chronic methamphetamine addiction, a medical consequence of methamphetamine use; a behavioral consequence of methamphetamine use, an HIV associated cognitive motor disorder, an HIV-associated neurodegenerative disorder, and a neuroinflammatory response.

Claim (Index 30):
The method of  claim 29  further comprising administering a therapeutically effective amount of one or more of an agonist (activator) of potassium-chloride co-transporter 2 (KCC2) and an inhibitor (antagonist) of 20 alpha-hydroxysteroid dehydrogenase (20 alpha-HSD) and therapeutically acceptable salt, solvate, clathrate, stereoisomer, enantiomer or prodrug of these compounds or mixtures thereof.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 94.0
- Lexical Diversity: 1.5
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15996937', '12093048', '12452482', '14736619', '10340957']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7204751947771465
- 35 USC 102 Novelty (BERT): 0.6695539191322982
- Combined Prediction Score: 0.7153830672126618
- Mean Citation Score: 333.7627740000001
- Max Citation Score: 790.53094
- Similarity Product: 619.3764333558607

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test